Axsome Therapeutics vs Harmony Biosciences
AXSM and HRMY side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXSM and HRMY compare
Axsome Therapeutics is the larger company, worth 3.7 times as much as Harmony Biosciences ($7.1B against $1.9B).
Axsome Therapeutics grew revenue faster over the last twelve months (56.9% versus 24.3% for Harmony Biosciences).
Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.9% compared with −24.7% at Axsome Therapeutics.
Harmony Biosciences scores higher on the StockData Score (18 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXSM | HRMY |
|---|---|---|
| Size and price | ||
| Market cap | $7.1B | $1.9B |
| Share price | $135.95 | $33.01 |
| Change, 1 year | −2.7% | −3.0% |
| Change, 5 years | 268% | −12.1% |
| Beta (5Y) | 0.87 | 1.11 |
| Employees | 500 | 293 |
| StockData Score | ||
| Total score | 8 | 18 (better) |
| Valuation score | 0 | 6 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 10.7× |
| P/S | 9.2× | 2.0× (better) |
| P/B | 85.5× | 1.9× (better) |
| EV/EBITDA | – | 6.1× |
| FCF yield | −1.0% | – |
| Fair value | – | $53.99 |
| Margin of safety | – | 38.9% |
| Growth | ||
| Revenue growth (TTM) | 56.9% (better) | 24.3% |
| Revenue growth, 5Y average | – | 40.3% |
| Net income growth (TTM) | – | 0.20% |
| EPS growth (TTM) | – | −0.32% |
| Profitability | ||
| Gross margin | 93.2% (better) | 75.4% |
| Operating margin | −24.0% | 24.0% (better) |
| Net margin | −24.7% | 18.9% (better) |
| FCF margin | −9.3% | – |
| Return on equity | −245% | 20.5% (better) |
| Return on invested capital | – | 40.1% |
| Financial health | ||
| Debt / equity | 2.26 | 0.15 (better) |
| Net debt / EBITDA | – | −2.23 |
| Interest coverage | – | 17.1× |
| Current ratio | 1.43 | 3.48 (better) |
| Altman Z-score | 4.21 | 5.12 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | −0.50% | – |
| Shareholder yield | −0.50% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 73.8% | 93.0% |
| Held by insiders | 15.2% | 12.1% |
| Insider net buying, 12 months | −$113M | −$5.8M (better) |
| Short interest, % of float | 7.3% | 13.0% |
Go deeper
- AXSM stock overview
- AXSM income statement
- AXSM valuation and score
- HRMY stock overview
- HRMY income statement
- HRMY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.